Clinical trials: Covid19- Coronavirus- Sars-cov-2
COVID-19, SARS-CoV 2
Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers
The investigators will follow a single prospective cohort of 50 Health Care Workers in the Hospital Italiano de Buenos Aires (Argentina) from May 15th to August 31st 2020 using antibody testing for SARS-CoV-2 IgM and IgG at…
- Conditions
- COVID-19, SARS-CoV 2, Health Personnel
- Trial name
- NCT04387890
- Testing
- Serologic SARS-CoV-2 screening
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Post-COVID-19 Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.
- Trial name
- NCT05497089
- Testing
- Temelimab 54mg/kg
- Where
- 14 sites in Italy, Spain and 1 more
- Volunteers
- 203 people
- Sponsor
- GeNeuro SA
COVID-19, SARS-CoV 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT04358068
- Testing
- Hydroxychloroquine (HCQ), Azithromycin (Azithro)
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID 19
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
Patients with mild and severe coronavirus disease 2019 (COVID 19) will be randomized 3:1:1:3 into four groups: colchicine, ruxolitinib, secukinumab, and control groups. .
- Trial name
- COLORIT (NCT04403243)
- Testing
- Colchicine, Ruxolitinib 5 MG, Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- Lomonosov Moscow State University Medical Research and Educational Center
SARS-CoV Infection, Covid19
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
This is a prospective, multicentric, non comparative study aiming to evaluate the clinical and virological evolution of high-risk patients infected with SARS-CoV-2 treated withtin the framework of a cohort ATU ('Autorisation…
- Trial name
- NCT04885452
- Testing
- biobank
- Where
- 37 sites in France
- Volunteers
- 756 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Covid19
COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7
Investigators study meet the World Health Organization definition of a clinical trial because it is a prospective study in which participants will be assigned to intervention groups to investigate the effects on health outcomes.
- Trial name
- Tomeka (NCT04537585)
- Testing
- Tomeka®, "Vernonia amygdalina"
- Where
- Democratic Republic of the Congo
- Volunteers
- 2,000 people
- Sponsor
- Guyguy K Tshima, MD
COVID-19, SARS CoV 2 Virus
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in…
- Conditions
- COVID-19, SARS CoV 2 Virus, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- COVID-19 (NCT06402318)
- Testing
- A&M Breathalyzer PROTECT Kiosk
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Geneva Foundation
Covid19
A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants
This is a Phase I single-dose study to investigate the pharmacokinetics, safety, and tolerability of sotrovimab vs placebo by intravenous or intramuscular administration in healthy Japanese and Caucasian participants.
- Trial name
- NCT04988152
- Testing
- sotrovimab
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Covid19
COVID-19 SAFE Enrollment
In order to safely and effectively reopen businesses and universities across the US, institutions will need to develop approaches to rapidly identify COVID-19 cases and manage their spread while balancing program effectiveness…
- Trial name
- COVID SAFE (NCT04506268)
- Testing
- Opt-out Recruitment Email, Opt-in Recruitment Email
- Where
- United States
- Volunteers
- 412 people
- Sponsor
- University of Pennsylvania
Acute Myocarditis
Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases
To date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood.
- Trial name
- MYOCOVID (NCT04375748)
- Testing
- Performing routine care (clinical and paraclinical tests), Examinations for the research:
- Where
- 65 sites in France, Martinique and 2 more
- Volunteers
- 756 people
- Sponsor
- University Hospital, Toulouse
Corona Virus Infection
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions
This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either…
- Trial name
- NCT04462848
- Testing
- anti-SARS-CoV-2 human convalescent plasma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Insomnia, COVID - 19
A Prospective Study: Tai-chi and Post-COVID Insomnia
The goal of this study is to see if Tai-Chi exercises (a type of Chinese martial arts) can help people suffering from insomnia after COVID-19 when added with cognitive-behavioral therapy (CBT) and drugs compared to CBT and drugs…
- Trial name
- insomnia (NCT06776276)
- Testing
- Tai Chi exercises
- Where
- Egypt
- Volunteers
- 337 people
- Sponsor
- Alexandria University
Covid-19
COVID-19 Convalescent Plasma for Mechanically Ventilated Population
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it can improve patients' health when they are sick with COVID-19.
- Trial name
- NCT04388527
- Testing
- COVID-19 Convalescent Plasma
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pennsylvania
COVID-19
Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)
COVID 19 which started from a zoonotic transmission related to crowded markets was confirmed to have a high potential for transmission to close contacts on 20 January 2020 by the National Health Commission of China and it was…
- Trial name
- CCOVID-19 (NCT04535869)
- Testing
- Sofosbuvir 400 MG plus Daclatasvir 200mg
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mansoura University
COVID-19, SARS CoV 2 Infection
Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies
Natural infection, vaccines and treatments (like monoclonal antibodies) lead to the appearance of a neutralizing power in the serum (due to induced or injected antibodies).
- Trial name
- PNAS (NCT05315583)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
SARS (Severe Acute Respiratory Syndrome), Cytokine Storm
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure.
- Conditions
- SARS (Severe Acute Respiratory Syndrome), Cytokine Storm, ARDS, Human, COVID-19
- Trial name
- COVID-19-HBO (NCT04327505)
- Testing
- Hyperbaric oxygen
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 34 people
- Sponsor
- Karolinska Institutet
COVID-19
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days.
- Trial name
- NCT04313023
- Testing
- PUL-042 Inhalation Solution
- Where
- 15 sites in United States
- Volunteers
- 217 people
- Sponsor
- Pulmotect, Inc.
COVID-19
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of Boost-2867, given intramuscular (IM) with or without adjuvant or intranasal (IN) without adjuvant, as a booster dose to previously…
- Trial name
- NCT07221162
- Testing
- Aluminum Hydroxide Suspension, Boost-2867, CpG 7909
- Where
- 8 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing…
- Trial name
- C4591068 (NCT06703190)
- Testing
- Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Covid19
Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
This is a phase III, randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a candidate adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen)…
- Trial name
- NCT05005559
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 16,876 people, healthy volunteers welcome
- Sponsor
- Cinnagen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.